Evidence map›Paper›PMID 38361897›Full record

ArticleJournal of family medicine and primary care2023

Impact of Remdesivir on inflammatory and prognostic markers of COVID-19: Findings of an event-monitoring study.

Shruti Singh, Nishi Sinha, Pallavi Lohani, Neha Agarwal, Pratibha Singh, C M Singh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of family medicine and primary care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shruti SinghDepartment of Pharmacology, All India Institute of Medical Sciences, Patna, Bihar, India.
Nishi SinhaDepartment of Pharmacology, All India Institute of Medical Sciences, Patna, Bihar, India.
Pallavi LohaniDepartment of Community Medicine, HI-TECH Medical College, Rourkela, Orissa, India.
Neha AgarwalDepartment of Pharmacology, All India Institute of Medical Sciences, Patna, Bihar, India.
Pratibha SinghDepartment of Anaesthesiology, Maharshi Devraha Baba State Autonomous Medical College, Deoria, Uttar Pradesh, India.
C M SinghDepartment of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India.
All India Institute of Medical Sciences · INHi-Tech Medical College & Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Remdesivir is currently approved for treating hospitalised patients with COVID-19. However, it is a priority to monitor its safety and effectiveness in various clinical settings. This study was undertaken to assess the impact of remdesivir on inflammatory and prognostic markers of COVID-19. Materials and Methods: A hospital-based prospective longitudinal study was conducted over two months comprising event monitoring of COVID-19 patients administered remdesivir as per standard guidelines. The demographic details, risk factors and all baseline parameters were collected. The patients were followed up for the appearance of any adverse drug reactions (ADRs) after the start of remdesivir therapy from Day 1 to discharge or death every day. Repeat Lab tests were done on days 2, 4, 6 and 10 days to assess the impact of remdesivir on inflammatory and prognostic markers of COVID-19 over time. Significant predictors of survival in the cohort were also assessed. Results: A total of 60 COVID-19 patients were administered remdesivir. The mean age of the patients was 59.2 (+13.7) years. There was a significant improvement in the serum creatinine (decreased from 0.9 to 0.7 mg/dL), lymphocyte count {decreased from 9.2 to 7.3 (10 Conclusion: Remdesivir administration improved the prognostic biomarker profile in COVID-19 patients.

Indexed as

Adverse drug reaction profileInflammatory biomarkersPrognostic markersRemdesivirSurvival analysis

Identifiers

PMID38361897
PMCPMC10866280
OpenAlexW4389923467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.